Furthermore, the scientific literature has suggested that patients with unmutated IGHV have a worse prognosis than those with mutated IGHV; the status of IGHV and the TP53 mutations influence the choice of therapy for patients with CLL.33, 34, 35. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.